1. Home
  2. HTLD vs GERN Comparison

HTLD vs GERN Comparison

Compare HTLD & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartland Express Inc.

HTLD

Heartland Express Inc.

HOLD

Current Price

$14.82

Market Cap

738.1M

Sector

Industrials

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.34

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTLD
GERN
Founded
1978
1990
Country
United States
United States
Employees
N/A
258
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
738.1M
808.3M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
HTLD
GERN
Price
$14.82
$1.34
Analyst Decision
Hold
Hold
Analyst Count
6
3
Target Price
$11.50
$2.17
AVG Volume (30 Days)
660.9K
14.7M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
0.60%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$805,709,000.00
N/A
Revenue This Year
N/A
$26.91
Revenue Next Year
$8.36
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.00
$1.04
52 Week High
$16.64
$2.01

Technical Indicators

Market Signals
Indicator
HTLD
GERN
Relative Strength Index (RSI) 48.77 56.29
Support Level $14.24 $1.23
Resistance Level $16.64 $1.46
Average True Range (ATR) 0.52 0.08
MACD -0.12 0.02
Stochastic Oscillator 25.22 61.43

Price Performance

Historical Comparison
HTLD
GERN

About HTLD Heartland Express Inc.

Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: